Zostavax® contains a live attenuated varicella-zoster virus, containing 14 times more virus than childhood varicella vaccines. Administration to people who are immunocompromised is associated with risk of disseminated disease from the vaccine virus. Our new GP decision aid be used to assist in the identification of patients who may be contraindicated for the shingles vaccine.
For further info including new resources, please refer to our MVEC: Zoster page.